Autologous Serum Eardrops Therapy With a Chitin Membrane for Closing Tympanic Membrane Perforations

Kakehata, Seiji; Hirose, Yuki; Kitani, Rei; Futai, Kazunori; Maruya, Shin-ichiro; Ishii, Kenji; Shinkawa, Hideichi

doi:10.1097/mao.0b013e31817f73af

Cited by 32 publications

(24 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, Kakehata et al reported good results by using a new treatment for closing chronic TM perforation using autologous serum [18]. Both autologous serum and umbilical cord serum owe their efficacy to the presence of various growth factors, like EGF, acidic and FGF, PDGF, hepatocyte growth factor, vitamin A, transforming growth factor (TGF)-␤, substance P, insulin-like growth factor (IGF)-1, nerve growth factor (NGF), fibronectin, and serum antiproteases, such as ␣2-macroglobulin [19][20][21].…”

Section: Article In Pressmentioning

confidence: 97%

Regeneration of chronic tympanic membrane perforation using 3D collagen with topical umbilical cord serum

Jang

Cho

Yeo

et al. 2013

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Section: Article In Pressmentioning

confidence: 97%

Regeneration of chronic tympanic membrane perforation using 3D collagen with topical umbilical cord serum

Jang

Cho

Yeo

et al. 2013

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

“…The perforations were closed spontaneously or with a chitin sheet patch in most patients. For 12 patients, autologous serum ear drops and/or basic fibroblast growth factor with a chitin sheet patch therapy in the outpatient clinic [Kakehata et al, 2008] were performed and the perforations were closed successfully except in 1 patient. Small perforations remained in 2 patients.…”

Section: Side Effectsmentioning

confidence: 99%

Daily Short-Term Intratympanic Dexamethasone Treatment Alone as an Initial or Salvage Treatment for Idiopathic Sudden Sensorineural Hearing Loss

Kakehata¹,

Sasaki²,

Futai³

et al. 2010

Audiol Neurotol

Self Cite

View full text Add to dashboard Cite

Objective: Intratympanic (IT) steroid therapy has been proposed as an alternative treatment option for patients with idiopathic sudden sensorineural hearing loss (ISSNHL). However, the number and frequency of IT treatments and drug delivery methods remain to be determined. The purpose of this study was to evaluate the efficacy of daily short-term IT dexamethasone (DEX) treatment alone in ISSNHL patients using laser-assisted myringotomy (LAM) for the drug delivery route as an initial and/or salvage treatment. Study Design: Retrospective study. Setting: University hospital. Patients: Seventy-six ISSNHL patients receiving IT DEX. Patients with low-tone hearing loss, unilateral or bilateral fluctuating hearing loss or contralateral hearing loss were excluded. Intervention: DEX (4 mg/ml) was injected through a perforation made by LAM. IT DEX administration was performed on 8 sequential days. Main Outcome Measures: Pre- and postprocedure hearing levels. The average hearing level was determined by 5 frequencies (250, 500, 1000, 2000 and 4000 Hz). Results: Nineteen out of 76 patients fit the criteria for initial treatment in the study (group I), while 24 patients, who had failed systemic therapy, received salvage treatment (group S). The mean age of the patients in groups I and S was 56.2 years with a range from 31 to 73 years of age and 46.0 years with a range from 11 to 76 years of age, respectively. The mean number of days from onset of symptoms to IT therapy in groups I and S was 4.8 days with a range of 1–23 days and 15.3 days with a range of 6–28 days, respectively. In group I, 18 of the 19 patients (95%) showed improvement of more than 10 dB in the pure-tone audiogram, with a mean improvement of 40 dB. Twelve patients (63%) recovered completely and 16 patients (84%) demonstrated successful results with an improvement of more than 30 dB. In group S, 14 of the 24 patients (58%) showed improvement of more than 10 dB with a mean improvement of 16 dB. Two (8%) of the 7 patients (29%) with successful results recovered completely. Conclusions: Daily short-term IT DEX administration using LAM for ISSNHL patients without concurrent therapy showed a high response rate and high cure rate and proved to be an alternative therapeutic option to high-dose systemic steroids as a first- and/or second-line treatment.

show abstract

“…[26][27][28] Autologous serum has been used over the last two decades to promote the healing of epithelial and cartilaginous damage of both known and unknown aetiologies. 13,[29][30][31] At the same time, it includes various immunoglobulins (e.g. immunoglobulin G and immunoglobulin A) and lysozyme.…”

Section: Discussionmentioning

confidence: 99%

“…Blood samples were centrifuged for 5 minutes at 3000 revolutions per minute. 13 The resulting serum was placed in a dental syringe and stored at 4°C. In order to create ototoxicity, amikacin (Amikozit; EczacibasiZentiva, Istanbul, Turkey) was administered at a dose of 0.2 cc (80 mg/ml) via the intratympanic and intramuscular routes, respectively.…”

Section: Methodsmentioning

confidence: 99%

“…10,11 Recent studies have indicated the efficacy of autologous serum in the treatment of neurotrophic keratopathy, osteoarthritis, chronic graft-versus-host disease and tympanic membrane perforations. [11][12][13] In addition to treatment, autologous serum should be able to prevent or at least decrease cell damage via its anti-apoptotic factors. 14 It is these potentially beneficial substances that may provide medical benefits to diseased or damaged inner-ear cells and nerves, in a therapeutic and protective manner.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic and protective effects of autologous serum in amikacin-induced ototoxicity

et al. 2017

View full text Add to dashboard Cite

Objective: Possible therapeutic and protective benefits of intratympanic autologous serum application in amikacininduced ototoxicity were investigated.Methods: Twenty-four guinea pigs were separated equally into two groups: therapeutic (group A) and protective (group B). Transient evoked otoacoustic emissions were recorded before and after autologous serum application. Apoptotic cells were identified in the organ of Corti, spiral limbus and spiral ganglion by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling ('TUNEL') method.Results: Transient evoked otoacoustic emission responses at 1, 1.4 and 2.8 kHz improved without significance after autologous serum application in group A ( p > 0.05). A significantly protective effect of autologous serum was determined at 4 kHz in group B ( p < 0.05). There were significantly fewer apoptotic cells at the spiral limbus in the therapeutic and protective groups compared to the control group ( p < 0.05).Conclusion: Autologous serum may offer protection against ototoxicity-induced hearing loss, but it cannot restore hearing. Immunohistochemically, autologous serum significantly decreases activation of the intrinsic pathway of pro-apoptotic signalling in mesenchymal cells compared to neurons and neurosensory cells.

show abstract

Autologous Serum Eardrops Therapy With a Chitin Membrane for Closing Tympanic Membrane Perforations

Cited by 32 publications

References 15 publications

Regeneration of chronic tympanic membrane perforation using 3D collagen with topical umbilical cord serum

Regeneration of chronic tympanic membrane perforation using 3D collagen with topical umbilical cord serum

Daily Short-Term Intratympanic Dexamethasone Treatment Alone as an Initial or Salvage Treatment for Idiopathic Sudden Sensorineural Hearing Loss

Therapeutic and protective effects of autologous serum in amikacin-induced ototoxicity

Contact Info

Product

Resources

About